Response to

Lv, Fang; Cai, Xiaoling; Ji, Linong

Lv, Fang¹; Cai, Xiaoling¹; Ji, Linong¹

Response to "Denosumab and romosozumab do not increase the risk of cardiovascular events in patients with primary osteoporosis: a reanalysis of the meta-analysis"

Bone. May 2020;134:115271

Affiliations

¹Department of Endocrinology and Metabolism, Peking University People's Hospital, No. 11 Xizhimen South Street, Xicheng District, Beijing 100044, China
Links

DOI: 10.1016/j.bone.2020.115271

PubMed: 32248982

WoS: 000527850700012
History

Revised: 2020-05-1

Online: 2020-04-2

Cited Works (2)

Year	Entry
2014	McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A, Langdahl BL, Reginster J-Y, Zanchetta JR, Wasserman SM, Katz L, Maddox J, Yang Y-C, Libanati C, Bone HG. Romosozumab in postmenopausal women with low bone mineral density. NEJM. January 30, 2014;370(5):412-420.
2017	Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A. Romosozumab or alendronate for fracture prevention in women with osteoporosis. NEJM. October 12, 2017;377(15):1417-1427.